FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140410963> ?p ?o ?g. }

• W2140410963 endingPage "81" @default.
• W2140410963 startingPage "77" @default.
• W2140410963 abstract "Justification for the Use of Statins in Primary Prevention: An Intervention Trial Using Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality with statin treatment in patients with elevated C-reactive protein (CRP) and average cholesterol levels who were not eligible for lipid-lowering treatment on the basis of existing guidelines. The aim of this study was to determine the prevalence of eligibility and mortality in a general population sample on the basis of eligibility for statin treatment using the JUPITER criteria. The study group consisted of 30,229 participants in the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort, an observational study of US African American and white participants aged ≥45 years, enrolled in their homes from 2003 to 2007 and followed biannually by telephone. Among 11,339 participants age eligible for JUPITER and without vascular diagnoses or using lipid-lowering treatment, 21% (n = 2,342) met JUPITER entry criteria. Compared with JUPITER participants, they had similar low-density lipoprotein cholesterol and CRP levels, were more often women, were more often black, had metabolic syndrome, and used aspirin for cardioprotection. Over 3.5 years of follow-up, the mortality rate in REGARDS participants eligible for JUPITER was 1.17 per 100 patient-years (95% confidence interval 0.94 to 1.42). Compared with those otherwise JUPITER eligible who had CRP levels <2 mg/L (n = 2,620), those with CRP levels ≥2 mg/L had a multivariate-adjusted relative risk of 1.5 (95% confidence interval 1.1 to 2.2) for total mortality. In conclusion, 21% not otherwise eligible would be newly eligible for lipid lowering treatment on the basis of JUPITER trial eligibility. Justification for the Use of Statins in Primary Prevention: An Intervention Trial Using Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality with statin treatment in patients with elevated C-reactive protein (CRP) and average cholesterol levels who were not eligible for lipid-lowering treatment on the basis of existing guidelines. The aim of this study was to determine the prevalence of eligibility and mortality in a general population sample on the basis of eligibility for statin treatment using the JUPITER criteria. The study group consisted of 30,229 participants in the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort, an observational study of US African American and white participants aged ≥45 years, enrolled in their homes from 2003 to 2007 and followed biannually by telephone. Among 11,339 participants age eligible for JUPITER and without vascular diagnoses or using lipid-lowering treatment, 21% (n = 2,342) met JUPITER entry criteria. Compared with JUPITER participants, they had similar low-density lipoprotein cholesterol and CRP levels, were more often women, were more often black, had metabolic syndrome, and used aspirin for cardioprotection. Over 3.5 years of follow-up, the mortality rate in REGARDS participants eligible for JUPITER was 1.17 per 100 patient-years (95% confidence interval 0.94 to 1.42). Compared with those otherwise JUPITER eligible who had CRP levels <2 mg/L (n = 2,620), those with CRP levels ≥2 mg/L had a multivariate-adjusted relative risk of 1.5 (95% confidence interval 1.1 to 2.2) for total mortality. In conclusion, 21% not otherwise eligible would be newly eligible for lipid lowering treatment on the basis of JUPITER trial eligibility." @default.
• W2140410963 created "2016-06-24" @default.
• W2140410963 creator A5017302499 @default.
• W2140410963 creator A5023858070 @default.
• W2140410963 creator A5029419484 @default.
• W2140410963 creator A5040184271 @default.
• W2140410963 date "2010-01-01" @default.
• W2140410963 modified "2023-09-27" @default.
• W2140410963 title "Eligibility for Statin Therapy by the JUPITER Trial Criteria and Subsequent Mortality" @default.
• W2140410963 cites W1971658255 @default.
• W2140410963 cites W1985967126 @default.
• W2140410963 cites W2038155090 @default.
• W2140410963 cites W2069566342 @default.
• W2140410963 cites W2118310760 @default.
• W2140410963 cites W2124544064 @default.
• W2140410963 cites W2131137214 @default.
• W2140410963 cites W2137983259 @default.
• W2140410963 cites W2165884492 @default.
• W2140410963 cites W2547754122 @default.
• W2140410963 cites W3022401702 @default.
• W2140410963 cites W2337109902 @default.
• W2140410963 doi "https://doi.org/10.1016/j.amjcard.2009.08.650" @default.
• W2140410963 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2813463" @default.
• W2140410963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20102894" @default.
• W2140410963 hasPublicationYear "2010" @default.
• W2140410963 type Work @default.
• W2140410963 sameAs 2140410963 @default.
• W2140410963 citedByCount "10" @default.
• W2140410963 countsByYear W21404109632012 @default.
• W2140410963 countsByYear W21404109632015 @default.
• W2140410963 crossrefType "journal-article" @default.
• W2140410963 hasAuthorship W2140410963A5017302499 @default.
• W2140410963 hasAuthorship W2140410963A5023858070 @default.
• W2140410963 hasAuthorship W2140410963A5029419484 @default.
• W2140410963 hasAuthorship W2140410963A5040184271 @default.
• W2140410963 hasBestOaLocation W21404109632 @default.
• W2140410963 hasConcept C126322002 @default.
• W2140410963 hasConcept C2776839432 @default.
• W2140410963 hasConcept C2777628954 @default.
• W2140410963 hasConcept C2780499067 @default.
• W2140410963 hasConcept C2908647359 @default.
• W2140410963 hasConcept C44249647 @default.
• W2140410963 hasConcept C71924100 @default.
• W2140410963 hasConcept C99454951 @default.
• W2140410963 hasConceptScore W2140410963C126322002 @default.
• W2140410963 hasConceptScore W2140410963C2776839432 @default.
• W2140410963 hasConceptScore W2140410963C2777628954 @default.
• W2140410963 hasConceptScore W2140410963C2780499067 @default.
• W2140410963 hasConceptScore W2140410963C2908647359 @default.
• W2140410963 hasConceptScore W2140410963C44249647 @default.
• W2140410963 hasConceptScore W2140410963C71924100 @default.
• W2140410963 hasConceptScore W2140410963C99454951 @default.
• W2140410963 hasIssue "1" @default.
• W2140410963 hasLocation W21404109631 @default.
• W2140410963 hasLocation W21404109632 @default.
• W2140410963 hasLocation W21404109633 @default.
• W2140410963 hasLocation W21404109634 @default.
• W2140410963 hasOpenAccess W2140410963 @default.
• W2140410963 hasPrimaryLocation W21404109631 @default.
• W2140410963 hasRelatedWork W1578454478 @default.
• W2140410963 hasRelatedWork W2018379041 @default.
• W2140410963 hasRelatedWork W2043355960 @default.
• W2140410963 hasRelatedWork W2043695663 @default.
• W2140410963 hasRelatedWork W2069235834 @default.
• W2140410963 hasRelatedWork W2070576422 @default.
• W2140410963 hasRelatedWork W2944043838 @default.
• W2140410963 hasRelatedWork W2948005449 @default.
• W2140410963 hasRelatedWork W4220719784 @default.
• W2140410963 hasRelatedWork W4328049566 @default.
• W2140410963 hasVolume "105" @default.
• W2140410963 isParatext "false" @default.
• W2140410963 isRetracted "false" @default.
• W2140410963 magId "2140410963" @default.
• W2140410963 workType "article" @default.